Articles Related to azone
Preliminary Investigation of the Interaction of Misoprostol and Phenylbutazone on Bone Response to Injury in Horses
Phenylbutazone (PBZ) is commonly used in equine patients for treatment of orthopedic injuries. Phenylbutazone may adversely affect bone healing because of suppression of prostaglandin production. We hypothesized that administration of the prostaglandin analog misoprostol would enhance bone healing and mitigate the untoward effects of PBZ on bone response to injury in horses. The objectives of this study were to determine whether the administration of misoprostol would enhance bone healing and whether concurrent administration of PBZ and misoprostol would mitigate the untoward effects of phenylbutazone. Twenty horses were randomly assigned to one of four groups (n=5 per group): Group 1 (untreated control), Group 2 (phenylbutazone alone), Group 3 (misoprostol, alone), or Group 4 (concurrent treatment with phenylbutazone and misoprostol). A 4.5-mm diameter uni-cortical bone defect was created in one metacarpal III bone of all horses. Fluorochromic bone labels were administered intravenously on Days 0, 7, and 14. Computed tomographic osteoabsorptiometry and histomorphometric analyses were performed on the harvested metacarpal bones. Phenylbutazone treatment caused a decrease in endosteal new bone formation. Administration of misoprostol appeared to mitigate the magnitude of the PBZ effect on new bone formation (endosteal in-growth, p<0.06). Bone specific alkaline phosphatase serum activity decreased throughout the 14-day period of stall confinement. Mineral apposition rates increased in all groups during the period from 7 to 14 days after bone injury. Further research is needed to determine if this effect is significant. The administration of misoprostol may be beneficial to lessen the undesired impact of phenylbutazone on bone healing in horses.
Effects of Pioglitazone on the Electrocardiogram in the Goto-Kakizaki Type 2 Diabetic Rat Heart
Cardiovascular complications are the major cause of morbidity and mortality in diabetic patients. Pioglitazone (PIO) is used for the
treatment of type 2 diabetes mellitus and there is some evidence that it may improve ventricular function in diabetic patients.
Review on Transdermal Drug Delivery Systems
Recently, transdermal drug delivery system (TDDS) has become a more and more important approach to administering drugs. Based on its advantages, which are not achievable by other modes of administration, many researchers are dedicated to the study of it, and have made great progress. Although the skin offers a painless interface for systemic drug delivery, it also presents limitations which are mainly caused by the stratum corneum.